Head-to-head evidence
Risperidone (QUAR) vs Risperidone (Risvan)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Risperidone (QUAR)
Developed by Laboratorios Farmacéuticos Rovi, S.A.
NCT06276361 · Phase 1 · completed
A sequential, open-label pharmacokinetic study of quarterly-injection risperidone in 58 participants, with pharmacokinetic parameters as the primary measures. The design is uncontrolled for treatment effect and no results have been posted to the registry, so this is weak evidence.
Next expected readout: December 2027 · NCT07047651 (registry estimate)
Risperidone (Risvan)
Marketed by Laboratorios Farmacéuticos Rovi, S.A.
NCT03160521 · Phase 3 · completed
The study randomized 438 participants to two risperidone doses or placebo under triple masking, with 390 participants included in the reported primary efficacy analysis. The clinical primary endpoint was the change in PANSS total score, reported as -24.6 and -24.7 points with risperidone versus -11.0 with placebo, but statistical significance for this primary comparison is not stated, so the result remains unclear.
Next expected readout: December 2027 · NCT07047651 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Risperidone (QUAR)'s landscape · Risperidone (Risvan)'s landscape